STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines
Authors:
- 23 April 2023
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 18 (8) , 1070-1081
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumorsCell Death & Disease, 2012
- Radiation Therapy Definitions and Reporting Guidelines for Thymic MalignanciesJournal of Thoracic Oncology, 2011
- Platelet‐derived growth factor and platelet‐derived growth factor receptor‐α expression in the normal human thymus and thymomaInternational Journal of Experimental Pathology, 2011
- Epidemiology of Thymoma and Associated MalignanciesJournal of Thoracic Oncology, 2010
- Expression and Mutational Status of c-kit in Thymic Epithelial TumorsJournal of Thoracic Oncology, 2010
- Insulin‐like growth factor‐1 receptor and phosphorylated AKT‐serine 473 expression in 132 resected thymomas and thymic carcinomasCancer, 2010
- Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic CarcinomasJournal of Thoracic Oncology, 2009
- Mutational status of EGFR and KIT in thymoma and thymic carcinomaLung Cancer, 2008
- Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymusAnnals of Anatomy - Anatomischer Anzeiger, 2008
- Thymic Carcinoma with Overexpression of MutatedKITand the Response to ImatinibNew England Journal of Medicine, 2004